AIHealthcare

Teal Health is a San Francisco-based, woman-led virtual women’s-health company focused on cervical-cancer screening rather than an AI-first healthcare product. Its core offering combines the FDA-authorized Teal Wand, an at-home vaginal self-collection device, with a telehealth service in which clinicians prescribe the kit, review laboratory results, and coordinate follow-up. The collected sample is tested using Roche’s cobas primary HPV assay. Teal announced FDA authorization of the Teal Wand on May 9, 2025, describing it as the first and only at-home self-collection device authorized in the U.S. for cervical-cancer screening; it subsequently announced availability in all 50 states in January 2026. The company raised an additional $10M seed round in January 2025, bringing publicly reported total funding at that time to $23M. The round was led by Emerson Collective and Forerunner, with participation/support from Serena Ventures, Metrodora, and Labcorp. Public sources identify Kara Egan as co-founder and CEO and Ave (Avnesh) Thakor as co-founder. No factual basis was found to classify Teal Health itself as an AI healthcare company, so its sector is characterized as virtual women’s health / medtech.